Literature DB >> 17645503

A randomized study of screening for ovarian cancer: a multicenter study in Japan.

H Kobayashi1, Y Yamada, T Sado, M Sakata, S Yoshida, R Kawaguchi, S Kanayama, H Shigetomi, S Haruta, Y Tsuji, S Ueda, T Kitanaka.   

Abstract

Ovarian cancer is common in women from developed countries. We designed a prospective randomized controlled trial of ovarian cancer screening to establish an improved strategy for the early detection of cancers. Asymptomatic postmenopausal women were randomly assigned between 1985 and 1999 to either an intervention group (n = 41,688) or a control group (n = 40,799) in a ratio of 1:1, with follow-up of mean 9.2 years, in Shizuoka district, Japan. The original intention was to offer women in the intervention group annual screens by gynecological examination (sequential pelvic ultrasound [US] and serum CA125 test). Women with abnormal US findings and/or raised CA125 values were referred for surgical investigation by a gynecological oncologist. In December 2002, the code was broken and the Shizuoka Cohort Study of Ovarian Cancer Screening and Shizuoka Cancer Registry were searched to determine both malignant and nonmalignant diagnoses. Twenty-seven cancers were detected in the 41,688-screened women. Eight more cancers were diagnosed outside the screening program. Detection rates of ovarian cancer were 0.31 per 1000 at the prevalent screen and 0.38-0.74 per 1000 at subsequent screens; they increased with successive screening rounds. Among the 40,779 control women, 32 women developed ovarian cancer. The proportion of stage I ovarian cancer was higher in the screened group (63%) than in the control group (38%), which did not reach statistical significance (P = 0.2285). This is to our knowledge the first prospective randomized report of the ovarian cancer screening. The rise in the detection of early-stage ovarian cancer in asymptomatic postmenopausal women is not significant, but future decisions on screening policy should be informed by further follow-up from this trial.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17645503     DOI: 10.1111/j.1525-1438.2007.01035.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  68 in total

1.  Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.

Authors:  Sarah J Nyante; Amanda Black; Aimée R Kreimer; Máire A Duggan; J Daniel Carreon; Bruce Kessel; Saundra S Buys; Lawrence R Ragard; Karen A Johnson; Barbara K Dunn; Lois Lamerato; John M Commins; Christine D Berg; Mark E Sherman
Journal:  Gynecol Oncol       Date:  2010-12-07       Impact factor: 5.482

2.  Intellectual dishonesty.

Authors:  Athol Kent
Journal:  Rev Obstet Gynecol       Date:  2012

3.  Abnormal CA-125 levels in menopausal women without ovarian cancer.

Authors:  Keith Y Terada; Jennifer Elia; Robert Kim; Michael Carney; Hyeong Jun Ahn
Journal:  Gynecol Oncol       Date:  2014-08-13       Impact factor: 5.482

4.  S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

Authors:  U Wagner; P Harter; F Hilpert; S Mahner; A Reuß; A du Bois; E Petru; W Meier; P Ortner; K König; K Lindel; D Grab; P Piso; O Ortmann; I Runnebaum; J Pfisterer; D Lüftner; N Frickhofen; F Grünwald; B O Maier; J Diebold; S Hauptmann; F Kommoss; G Emons; B Radeleff; M Gebhardt; N Arnold; G Calaminus; I Weisse; J Weis; J Sehouli; D Fink; A Burges; A Hasenburg; C Eggert
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-09       Impact factor: 2.915

5.  Ovarian Cancer Prevention, Screening, and Early Detection: Report From the 11th Biennial Ovarian Cancer Research Symposium.

Authors:  Jeremy Chien; Elizabeth M Poole
Journal:  Int J Gynecol Cancer       Date:  2017-11       Impact factor: 3.437

6.  Selected medical interventions in women with a deleterious BRCA mutation: a population-based study in British Columbia.

Authors:  G E Hanley; J N McAlpine; R Cheifetz; K A Schrader; M McCullum; D Huntsman
Journal:  Curr Oncol       Date:  2019-02-01       Impact factor: 3.677

Review 7.  Novel Approaches to Ovarian Cancer Screening.

Authors:  Denise R Nebgen; Karen H Lu; Robert C Bast
Journal:  Curr Oncol Rep       Date:  2019-07-26       Impact factor: 5.075

Review 8.  Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.

Authors:  Henry T Lynch; Murray Joseph Casey; Carrie L Snyder; Chhanda Bewtra; Jane F Lynch; Matthew Butts; Andrew K Godwin
Journal:  Mol Oncol       Date:  2009-02-21       Impact factor: 6.603

9.  A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort.

Authors:  Kathryn L Terry; Helena Schock; Renée T Fortner; Anika Hüsing; Raina N Fichorova; Hidemi S Yamamoto; Allison F Vitonis; Theron Johnson; Kim Overvad; Anne Tjønneland; Marie-Christine Boutron-Ruault; Sylvie Mesrine; Gianluca Severi; Laure Dossus; Sabina Rinaldi; Heiner Boeing; Vassiliki Benetou; Pagona Lagiou; Antonia Trichopoulou; Vittorio Krogh; Elisabetta Kuhn; Salvatore Panico; H Bas Bueno-de-Mesquita; N Charlotte Onland-Moret; Petra H Peeters; Inger Torhild Gram; Elisabete Weiderpass; Eric J Duell; Maria-Jose Sanchez; Eva Ardanaz; Nerea Etxezarreta; Carmen Navarro; Annika Idahl; Eva Lundin; Karin Jirström; Jonas Manjer; Nicholas J Wareham; Kay-Tee Khaw; Karl Smith Byrne; Ruth C Travis; Marc J Gunter; Melissa A Merritt; Elio Riboli; Daniel W Cramer; Rudolf Kaaks
Journal:  Clin Cancer Res       Date:  2016-04-08       Impact factor: 12.531

10.  The preclinical natural history of serous ovarian cancer: defining the target for early detection.

Authors:  Patrick O Brown; Chana Palmer
Journal:  PLoS Med       Date:  2009-07-28       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.